Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sequential Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective Double-Blinded Randomized Controlled Trial Publisher



Tabesh E1 ; Yadmehr F2 ; Feizi A3 ; Khorvash F4 ; Sindarreh S5 ; Hakamifard A2, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Cancer Prevention Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Health Science Reports Published:2024


Abstract

Backgrounds and Aims: This controlled randomized clinical trial was designed to compare effectiveness, side effects, and severity of symptoms before and after therapy between quadruple (QT) and sequential regimens (SQ) for Helicobacter Pylori (H. pylori). Methods: Patients were randomly allocated into two groups. Group A received a 14-day QT including pantoprazole 40 mg q12 h, bismuth subcitrate 240 mg q12 h, clarithromycin 500 mg q12 h, and amoxicillin 1000 mg q12 h and group B received ST including pantoprazole 40 mg q12 h and amoxicillin 1000 mg q12 h for the initial 5 days followed by pantoprazole 40 mg q12 h, clarithromycin 500 mg q12 h and tinidazole 500 mg q12 h for the next 5 days. Adverse drug reactions and patients' compliance were assessed after finishing the treatment course and also 4 weeks after. All patients were naive, therefore ST and QT were first-line therapies. To evaluate severity of symptoms we used Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) before taking the first dose of regimens, at the end of therapy, and also 4 weeks after (follow-up). Results: The mean age in Group A (n = 83) was 48.55 ± 12.56 and 47.24 ± 12.78 in Group B (n = 79). No statistically significant differences were observed between the two groups regarding age, gender, endoscopic findings, and also eradication rate. The analysis demonstrated a significant decrease in SF-LDQ score between baseline and after therapy and baseline and follow-up in both regimen groups. Both regimens were well tolerated by the majority of patients, and there were no significant differences between the two groups in terms of adverse drug reactions. Conclusion: This study showed that ST can be used as an alternative first-line therapy to QT in patients with H. pylori infection. © 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Experts (# of related papers)
Other Related Docs
18. Helicobacter Pylori in Iran: A Systematic Review on the Antibiotic Resistance, Iranian Journal of Basic Medical Sciences (2015)
24. Is Helicobacter Pylori Infection Prevalent in Middle East Countries?, Archives of Clinical Infectious Diseases (2022)